CTIS2023-507409-32-00
Active, not recruiting
Phase 1
A study to investigate the safety, pharmacodynamics and pharmacokinetics of increasing doses of subcutaneously administered deuterated DMT (CYB004) in healthy subjects
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Cybin IRL Limited
- Enrollment
- 72
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A study to investigate the pharmacodynamics, safety and tolerability of cutaneous capsaicin in healthy adult subjects.Small fibre neuropathy10034606NL-OMON37233Centre for Human Drug Research12
Completed
Not Applicable
A study to evaluate the pharmacokinetics, safety and tolerability after inhalation of MMI-0100 in healthy subjects; MMI-0100 is an investigational drug developed for the treatment of fibrotic indications.idiopathische fibroseIdiopathic pulmonary fibrosispulmonary diseases.NL-OMON40896Moerae Matrix, Inc48
Completed
Not Applicable
A study evaluating the pharmacokinetics, safety and tolerability of OP2113 administered intravenously in healthy volunteers and a marketed formulation administered orallyNL-OMON48072OP2 Drugs12
Active, not recruiting
Not Applicable
Study to evaluate the safety and pharmacokinetics of ciprofloxacin following inhalation of ciprofloxacin dry powder for inhalation administered to pediatric patients with cystic fibrosis aged 12-17 yearslong term treatment of chronic lung infections caused by Pseudomonas aeruginosa in patients with cystic fibrosisMedDRA version: 8.1Level: LLTClassification code 10011763Term: Cystic fibrosis lungEUCTR2007-002912-24-DEBayer HealthCare AG16
Completed
Not Applicable
The aim of this study is to compare and evaluate the pharmacokinetic properties and safety of oral administration of test drugEndocrine, nutritional and metabolic diseasesKCT0004026Kyung Dong Pharmaceutical80